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Histone deacetylase inhibitor SAHA 
attenuates post-seizure hippocampal microglia 
TLR4/MYD88 signaling and inhibits TLR4 gene 
expression via histone acetylation
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Abstract 
Background: Epilepsy is a common neurological disorder characterized by recurrent unprovoked seizures. Seizure‑
induced TLR4/MYD88 signaling plays a critical role in activating microglia and triggering neuron apoptosis. SAHA is 
a histone deacetylase inhibitor that regulates gene expression by increasing chromatin histone acetylation. In this 
study, we investigated the role of SAHA in TLR4/MYD88 signaling in a rat seizure model.
Results: Sprague–Dawley rats with kainic acid (KA)‑induced seizures were treated with SAHA. The expression of TLR4, 
MYD88, NF‑κB P65 and IL‑1β in hippocampus was detected at hour 2 and 6 and day 1, 2, and 3 post seizure. SAHA 
pretreatment increased seizure latency and decreased seizure scores. The expression levels of TLR4, MYD88, NF‑κB and 
IL‑1β increased significantly in both activated microglia and apoptotic neurons after KA treatment. The effects were 
attenuated by SAHA. Chromatin immunoprecipitation assays indicated that the H3 histone acetylation levels signifi‑
cantly decreased while H3K9 levels significantly increased in the KA treatment group. The H3 and H3K9 acetylation 
levels returned to control levels after SAHA (50 mg/kg) pretreatment. There was a positive correlation between the 
expression of TLR4 and the acetylation levels of H3K9.
Conclusions: Histone deacetylase inhibitor SAHA can suppress seizure‑induced TLR4/MYD88 signaling and inhibit 
TLR4 gene expression through histone acetylation regulation. This suggests that SAHA may protect against seizure‑
induced brain damage.
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Background
Epilepsy is among the most common brain disorders 
[1]. Previous studies suggest that inflammation plays an 
important role in epilepsy development [2–6]. Seizure-
induced inflammation can generate a negative feedback 
loop on neurons [7]. Microglia secretes cytokines (e.g. 
IL-1β and TNF-α) during CNS pathological processes 
[8].
Astrocytes and microglia express toll-like-receptor 
(TLR) family member proteins such as TLR3 and TLR4 
[9–12]. Expressed in microglia [13–15], TLR4 is closely 
involved in microglia inflammation responses [16]. Thus, 
inhibiting TLR4-mediated microglia activation in inflam-
matory responses could have neuroprotective effects. It 
has been shown that systemic administration of kainic 
acid (KA) can induce epileptic seizures, which causes 
neuroinflammation or neuronal cell death in the hip-
pocampus CA1 and CA3 regions in animals [17–20].
Numerous studies have shown the potential of histone 
deacetylase (HDAC) inhibitors as novel therapeutics 
for ischemic stroke [21–23], multiple sclerosis [24] and 
Huntington’s disease [25, 26]. Histone acetyltransferases 
(HATs) and HDACs reportedly determine the post-
translational acetylation status of chromatin [27]. While 
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HATs leads to a transcriptionally-active chromatin struc-
ture, HDACs deacetylate and suppress transcription [28]. 
Therefore, HDAC inhibitors usually reactivate silenced 
genes [27, 28].
TLR4 signaling leads to activation of two major sig-
nal transduction pathways: the myeloid differentiation 
primary response protein 88 (MyD88)-dependent and 
MyD88-independent pathways [29]. Previous studies 
have suggested a key role of MyD88-dependent signaling 
in developing brain injuries [29, 30]. The role of microglia 
TLR4/MyD88 signaling in regulating neuronal cell death 
and release of inflammatory cytokines following KA-
stimulation is, as yet, largely unknown.
In this study, we for the first time explored the role of 
SAHA in TLR4/MYD88 signaling and histone acetylation 
of TLR4 gene in KA-induced seizures.
Methods
Animals
Developing male Sprague–Dawley rats (3  weeks old, 
weighing 60–80 g) were obtained from the Experimental 
Animal Center of Hunan University of Chinese Medicine 
(Changsha, Hunan, China). The animals were housed in 
conventional conditions at 22 °C, 50–60 % humidity with 
alternating 12 h light/12 h dark cycles. Rats were allowed 
free access to food and water..
Seizure induction
Male Sprague–Dawley rats were used in this study and 
were randomly divided into four experimental groups: (1) 
control group (saline); (2) KA group; (3) “KA + 10 mg/
kg SAHA”group; and (4) “KA + 50 mg/kg SAHA” group. 
Intraperitoneal administration of KA 15  mg/kg (Sigma, 
St Louis, MO, USA) was used to induce seizures. Rats 
were continuously monitored for seizure activity for 4 h 
after KA administration. Behavioral seizures were graded 
on the Racine scale [31]: stage 1, facial clonus; stage 2, 
head nodding; stage 3, forelimb clonus; stage 4, forelimb 
clonus with rearing; stage 5, rearing, jumping, and falling. 
SAHA (10 or 50 mg/kg; Sigma, St Louis, MO, USA) was 
injected intraperitoneally 30  min before KA injection. 
Seizure latency times and seizure scores were analyzed. 
After behavioral assessments, the rats were sacrificed 
with an anesthetic (1  % barbital sodium, 500  mg/kg) at 
different post-seizure time points (hour 2 and 6, and day 
1, 2, and 3). The rats were then perfused transcardially 
with saline and the hippocampi were immediately dis-
sected. Samples taken from rats sacrificed at the 2 h, 6 h, 
1 d and 2 d post-seizure time points were used for West-
ern Blot, qRT-PCR, and chromatin immunoprecipitation. 
The samples were preserved at −70 °C. Post-seizure rats 
sacrificed at the three-day mark were used to the experi-
ment of immunohistochemistry and TUNEL staining. 
Their brains were removed immediately and fixed over-
night using cold 4 % paraformaldehyde at 4 °C.
Western blotting
Harvested hippocampi were washed in ice-cold PBS 
and lysed for 10 min using an RIPA lysis buffer. Lysates 
were centrifuged and supernatant collected. The protein 
concentration in the lysate supernatant was measured 
with BCA protein assays (Beyotime, Shanghai, China). 
Western-blot was performed according to standard pro-
cedures. Briefly, equal amounts (30 μg) of proteins were 
separated electrophoretically by SDS-PAGE and then 
transferred to 0.22  mm polyvinylidene fluoride mem-
brane (PVDF; Millipore, Bedford, MA). The membranes 
were soaked in 5 % skimmed milk as blocking buffer for 
2  h and then incubated with appropriate primary anti-
bodies including mouse anti-TLR4 antibody (1:1000; 
Abcam), rabbit anti-MYD88 antibody (1:1000; Cell Sign-
aling, Beverly, MA, USA), rabbit anti-NF-kB P65 anti-
body (1:2000; Proteintech), rabbit anti-IL-1β antibody 
(1:500, Proteintech) and mouse anti-β-actin (1:2000; 
Abcam), respectively, at 4  °C overnight. After washing 
with phosphate-buffered saline containing 0.1 % Tween-
20 (PBST), the membranes were incubated with 5 % milk 
containing the corresponding peroxidase-conjugated 
secondary antibody (1:5000; Santa Cruz Biotechnology, 
CA, USA) for 1 h at room temperature. Following three 
washes in PBST, immunoreactive bands were visualized 
by enhanced chemiluminescence (ECL) (Santa Cruz, CA, 
USA). Band pattern was analyzed with Image Quant™ 
LAS 4000 (GE Healthcare, Shanghai, China).
Quantitative (q)RT‑PCR analysis
Total RNA was extracted from hippocampal tissues. 
Reverse transcription (RT) and Real time Quantitative 
polymerase chain reaction (qRT–PCR) were performed 
with GoScript™ Reverse Transcription kit (A5000; Pro-
mega, Madison, WI) and GoTaq® qPCR Master Mix kit 
(A6001; Promega, Madison, WI). qPCR primers were 
listed in Table 1. The PCR condition was as follows: for 
TLR4, Denaturation: 95 °C, 45 s; Annealing: 56 °C, 45 s; 
Extension: 72 °C, 1 min; 30 cycles; for MYD88, Denatura-
tion: 95 °C, 45 s; Annealing: 55 °C, 60 s; Extension: 72 °C, 
1  min; 30 cycles; for NF-kB P65, Denaturation: 95  °C, 
45 s; Annealing: 58 °C, 45 s; Extension: 72 °C, 1 min; 30 
cycles; for IL-1β, Denaturation: 95  °C, 45  s; Annealing: 
57 °C, 45 s; Extension: 72 °C, 1 min; 30 cycles; for β-actin, 
Denaturation: 95 °C, 30 s; Annealing: 60 °C, 30 s; Exten-
sion: 72 °C, 30 s; 26 cycles.
Immunohistochemistry: CD68 staining
Brain tissue was fixed in 4  % paraformaldehyde and 
embedded in paraffin. Hippocampal tissues were sliced 
Page 3 of 12Hu and Mao  BMC Neurosci  (2016) 17:22 
into 5-μm thick coronal sections in a cryostat. After 
dewaxing and hydrating, sections were treated with 3 % 
H2O2 for 30  min. After three PBS rinses, the sections 
were blocked using a 0.5 % bovine serum for 1 h at room 
temperature. The sections were then incubated over-
night at 4 °C with mouse polyclonal anti-CD68 antibody 
(1:100; AbD Serotec, Kidlington, UK) [32]. Sections were 
then incubated with a goat anti-mouse secondary anti-
body for 2 h followed by horseradish peroxidase (HRP)-
Streptavidin for 1  h at 37  °C. After three PBS rinses, 
sections were reacted with a 0.025 % 3, 3′-diaminoben-
zidine tetrahydrochloride (DAB) solution for 5  min. 
Finally, sections were mounted onto gelatin-coated glass 
slides and air-dried. We examined the slides with a Moti-
cam Pro microscope (Moticam, Xiamen, China). Image-
Pro Plus 6.0 software (Media Cybernetics, Bethesda, 
MD, USA) was used to calculate the CD68 stained area. 
The average optical density (mean density) represented 
the intensity of CD68 expression and was counted in 
four random fields in the hippocampal CA1 region per 
section.
TUNEL staining
TUNEL staining was performed using situ apoptosis 
detection kit (Millipore, Billerica, MA, USA). Tissue sec-
tions were treated with 3 % hydrogen peroxide to quench 
endogenous peroxidase activity. After adding a labeling 
buffer, sections were treated with terminal deoxynucle-
otidyl transferase (TdT) and digoxigenin dUTP for 2 h at 
37 °C. Specimens were then treated with peroxidase-cou-
pled anti-digoxigenin for 30  min at 37  °C. 3,3′-diamin-
obenzidine (DAB) was used to detect developing signals. 
Sections were counterstained with methyl green, rinsed, 
dehydrated, and mounted. The slides were examined by 
Moticam Pro microscope (Moticam, Xiamen, China). 
Each slice was observed using a high-power microscope 
on three visual fields of the hippocampus, and TUNEL 
positive cells were counted in each group.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed with chromatin immuno-
precipitation kit (Catalog No. 17-20000; Millipore, MA). 
Hippocampus tissue was exposed to 1  % formaldehyde 
to crosslink with DNA proteins, ensuring DNA co-pre-
cipitation with the protein of interest. Glycine was then 
added to each sample tube to quench unreacted formal-
dehyde. Hippocampus tissue was broken open with an 
SDS Lysis Buffer containing Protease Inhibitor Cocktail 
II. Sonication was performed to shear the chromatin to 
a manageable size. Generally between 200 and 1000 bp of 
DNA is small enough to achieve a high degree of reso-
lution during the detection step. The average fragment 
size is confirmed by gel electrophoresis. Protein G Aga-
rose (Millipore, Billerica, MA) was added to each IP tube 
to remove proteins, or DNA, that might nonspecifically 
bind to the protein G agarose. Precleared chromatin was 
immunoprecipitated using an anti-acetyl histone H3 
and H3K9 Ab (Millipore, Billerica, MA) or rabbit IgG as 
a control. It was then incubated overnight at 4  °C while 
being rotated. Protein G Agarose was added to each IP 
tube and incubated for 1 h at 4 °C with rotation in order 
to collect the antibody/antigen/DNA complex. After four 
sequential washes using four different wash buffers, the 
protein-DNA crosslinks were reversed during incubation 
at 65 °C. DNA was purified to remove chromatin proteins 
and to prepare it for the detection step. The TLR4 gene 
corresponding to 5′ promoter regions -627/-437 was 
amplified by PCR from the sheared DNA using the for-
ward primer 5′-ACAAACAAACAAACCCACCA-3′ and 
reverse primer 5′-TCCCACCTGTACTGCCTCTT-3′; 
GAPDH was amplified as a internal reference using the 
forward primer 5′-TACTAGCGGTTTTACGGGCG-3′ 
and reverse primer 5′-TCGAACAGGAGGAGCAGAG 
AGCGA-3′. PCR conditions were as follows: for TLR4, 
Denaturation: 95 °C, 45 s; Annealing: 58 °C, 45 s; Exten-
sion: 72 °C, 1 min; 35 cycles; for GAPDH, Denaturation: 
95  °C, 30  s; Annealing: 55  °C, 45  s; Extension: 72  °C, 
1  min; 30 cycles. PCR products were separated on 2  % 
agarose gel. Band density was measured using G: BOX 
Chemi XR5 Imaging System (Syngene, UK).
Statistical analysis
All data are presented as the mean  ±  SD. Differences 
among the means were analyzed by two-tailed Student 
t test or ANOVA followed by the Bonferroni’s post hoc 
test. P < 0.05 was considered statistically significant.
Results
SAHA attenuates KA‑induced seizures
KA induced seizure in 84 % of rats that did not receive 
SAHA, with 9  % mortality. Latency and seizure scores 
were 64.83  ±  13.99  min and 4.23  ±  0.94, respectively 
Table 1 Nucleotide sequences of  primers for  real time 
quantitative polymerase chain reaction
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(Fig.  1). Different seizure scores were observed in 
SAHA-treated rats (Table  2). The mean latency and 
seizure score for “KA  +  10  mg/kg SAHA” group was 
75.11  ±  14.27  min and 3.44  ±  1.56, and statistically 
different from the seizure control group (P  <  0.01 and 
P  <  0.05; Fig.  1; Table  2). The mean latency and sei-
zure score for “KA  +  50  mg/kg SAHA” group was 
103.68 ± 14.99 min and 2.37 ± 1.48, and statistically dif-
ferent from the seizure control group (P < 0.001; Fig. 1; 
Table 2). Further comparison showed that the above two 
data in “KA + 50 mg/kg SAHA” group were significantly 
different from “KA + 10 mg/kg SAHA” group (P < 0.01 
and P < 0.001; Fig. 1 and Table 2). SAHA (10 or 50 mg/
kg, i.p.) administration 30 min before KA administration 
increased the seizure latency and decreased the seizure 
score.
SAHA reduces KA‑induced neuronal cell death
TUNEL staining showed considerable neuronal apopto-
sis at hippocampal CA1 in the KA-injected rats (Fig. 2b). 
SAHA pretreatment (10 or 50  mg/kg) significantly 
attenuated KA-induced neuronal apoptosis (Fig.  2c, d). 
Figure  2a was the negative control group. In rats pre-
treated with SAHA 50  mg/kg, the number of TUNEL 
positive cells at CA1 decreased significantly in compari-
son to SAHA 10 mg/kg.
SAHA suppresses KA‑induced microglia activation
To examine whether SAHA affected inflammatory pro-
cesses in KA-injected rats, we analyzed microglia acti-
vation by detecting the expression of CD68, a marker 
of activated microglia. CD68 positive cells and intensity 
increased in KA-treated rats, but this increase was sup-
pressed by SAHA pretreatment (Fig. 3c, d). In the saline 
and SAHA (50  mg/kg)-treated rats, CD68 positive cells 
were sparse and CA1-region microglia showed a resting 
morphology with small cell bodies and long, thin, pro-
cesses (Fig. 3a). KA-injected rats had a notable increase 
in the number of activated microglia in the CA1 region. 
These cells displayed enlarged amoeboid morphology and 
fewer and shorter processes, which indicated the acti-
vation state (Fig.  3b). SAHA-pretreatment significantly 
suppressed KA-induced microglia activation (Fig. 3c, d).
SAHA reduces mRNA and protein levels of TLR4, MYD88, 
NF‑κB P65 and IL‑1β
To investigate the effect of SAHA on TLR4/MYD88 
signaling, Real-time qPCR and Western blot were used 
to measure gene expression and protein levels of TLR4, 
MYD88, NF-κB P65 and IL-1β. KA stimulation increased 
TLR4, MYD88, NF-κB P65 and IL-1β protein levels at 
2 h, 6 h, 1 d and 2 d after KA injection in hippocampus 
CA1 region. SAHA 50 mg/kg significantly attenuated the 
increases (Fig.  4). Further gene expression analyses by 
Real-time qPCR confirmed that TLR4, MYD88, NF-κB 
P65, and IL-1β mRNA levels were consistent with pro-
tein level tendencies (Fig. 5). These results suggested that 
SAHA could suppress seizures-induced TLR4/MYD88 
signaling.
Fig. 1 SAHA attenuated KA‑induced seizures behavior in rats. The 
rats were pretreated with SAHA (10 or 50 mg/kg, i.p.) 30 min before 
KA (15 mg/kg, i.p.) injection. Seizure latency was measured during 
1–4 h after KA administration. Data are expressed as mean ± SD. 
***P < 0.001; **P < 0.01 or *P < 0.05 versus KA‑treated group
Table 2 Rat seizure score
The rats in different seizures stage were counted and mean seizure score was analyzed by statistical method. Data are expressed as mean values ± SD
* P < 0.05; *** P < 0.001, as compared with the KA-treated group
No seizure Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Mean score
KA 0 0 3 3 12 17 4.23 ± 0.94
KA + SAHA 10 mg/kg 3 1 6 4 11 11 3.44 ± 1.56*
KA + SAHA 50 mg/kg 6 4 9 11 5 3 2.37 ± 1.48***
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Fig. 2 SAHA attenuated KA‑induced neuronal death in hippocampal CA1 region. SAHA (10 or 50 mg/kg) was administrated intraperitoneally 
30 min before KA injection. Neuronal apoptosis were evaluated 3 days after KA injection. (a–d) TUNEL staining of hippocampal CA1 pyramidal 
neurons; a control group, b KA group, c KA + 10 mg/kg SAHA group, d KA + 50 mg/kg SAHA group, e TUNEL positive cells quantities for each 
group. Data are expressed as mean ± SD. Scale bar = 100 μm. *P < 0.05, KA group versus KA + 10 mg/kg SAHA group; **P < 0.01, KA group versus 
KA + 50 mg/kg SAHA group; ***P < 0.001, KA group versus control group; #P < 0.001, KA + 10 mg/kgSAHA group versus KA + 50 mg/kg SAHA 
group
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Fig. 3 SAHA attenuated KA‑induced microglia activation in the hippocampal CA1 region. SAHA (10 or 50 mg/kg) was administrated intraperito‑
neally 30 min before KA injection, and the hippocampal sections were stained with anti‑CD68 antibody 3 days after KA injection. (a–d) CD68 immu‑
nostaining of activated microglia in hippocampal CA1 region; a control group; b KA group; c KA + 10 mg/kg SAHA group; d KA + 50 mg/kg SAHA; 
e Average optical density of CD68 immunoreactive cells in each group. Insets in a and b show morphological change after KA administration under 
higher magnification. Data are expressed as mean ± SD, Scale bar = 100 μm for a–d. *P < 0.01 versus control group;  #P < 0.01 versus KA group
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Fig. 4 SAHA inhibited TLR4 signal pathway in KA‑induced seizures. The protein expression of TLR4, MYD88, NF‑κB P65 and IL‑1β were examined by 
immunoblots at 2, 6 h, 1 d and 2 d after KA injection in hippocampus CA1 region. Specific bands were quantified by densitometry and data were 
expressed as mean ± SD (n = 3); #P < 0.01 versus control group; *P < 0.01 versus KA‑treated group
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SAHA inhibits TLR4 gene transcription by histone 
acetylation regulation
Twenty-four hours after KA-induced seizures, histone 
acetylation on the TLR4 gene 5′ region was analyzed by 
ChIP assays using anti-acetyl histone H3, and H3K9 anti-
bodies. As shown in Fig. 6, H3 histone acetylation levels 
significantly decreased while H3K9 significantly increased 
in the KA treatment group when compared to the control 
group. H3 and H3K9 acetylation level returned to control 
levels after SAHA 50 mg/kg pretreatment (Fig. 6a–d). The 
mRNA expression of TLR4 increased significantly with 
KA treatment, which was reversed by SAHA (Fig.  5a). 
The results suggested that the expression of TLR4 was 
dependent on the acetylation levels of H3K9; SAHA led to 
hypoacetylation of H3K9, which in turn resulted in down-
regulation of the expression of TLR4.
Fig. 5 SAHA attenuated KA‑induced mRNA expression of TLR4, MYD88, NF‑κB and IL‑1β in hippocampus. In hippocampus CA1 region, mRNA 
expression of TLR4, MYD88, NF‑κB and IL‑1β were measured with real‑time Quantitative PCR at 2, 6 h, 1 d and 2 d after KA injection. Relative quantifi‑
cation data were expressed as mean ± SD (n = 3). #P < 0.01 versus control group; *P < 0.01 versus KA‑treated group
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Discussion
To date, the understanding of potential protective mech-
anisms and pathogenesis of seizures-induced brain injury 
is still very limited [33–35]. We hypothesized that SAHA 
would have an anticonvulsant effect. This study shows 
that SAHA has an anticonvulsant effect in a KA seizure 
model in rats. We chose this model because KA-induced 
seizure activity and brain damage are similar to those in 
humans [17, 36, 37] and are associated with excessive 
glutamate release [38–40]. In agreement with previous 
studies, KA injection (15  mg/kg, i.p.) induced epileptic 
seizures in this study [36, 41–43]. SAHA pretreatment 
(10 or 50  mg/kg) reduced KA-induced neuronal apop-
tosis, suggesting SAHA as a potent neuroprotective and 
anticonvulsant agent.
Previous studies suggest that KA-induced microglia 
activation can cause hippocampal neuron apoptosis 
[44–46]. Therefore, preventing microglia activation pro-
tects hippocampus against neuron apoptosis caused by 
KA-induced seizures [47]. In this study, we noted that the 
number of activated microglia immunostained for CD68, 
a marker for microglia activation [48], was significantly 
higher in the hippocampus in KA-treated rats. SAHA 
pretreatment reduced the number of activated micro-
glia. Thus, SAHA may have an anti-inflammatory func-
tion and neuroprotective effects. However, how SAHA 
affects microglia activation remains unclear. Microglia 
activation and subsequent production of pro-inflam-
matory cytokines are believed to contribute to neuronal 
damage [49, 50]. Thus, there might be a direct interac-
tion between SAHA and these factors; this needs to be 
explored in future studies.
A previous study reported that a functional TLR4/
MyD88 cascade in microglia was essential for neuronal 
injury [51–55]. In this study, our findings indicate that 
SAHA attenuated the inflammatory mediators produc-
tion by inhibiting the TLR4/MyD88 signaling pathway 
associated with activated microglia. Thus, the anti-neu-
roinflammation effect of SAHA on activated microglia 
may contribute to the treatment of conditions relating to 
inflammatory response.
In this study, ChIP experiments indicated that KA 
increased histone H3 acetylated at lysine 9 (H3K9) 
of TLR4 gene and SAHA pretreatment reversed the 
increase. Lysine acetylation is a common post-transla-
tional modification on both histones and non-histones; 
hyperacetylation of lysine is conventionally associated 
with enhanced gene expression [56]. This means that 
TLR4 gene transcription is epigenetically suppressed by 
adding SAHA in KA-induced seizures, as found in this 
study. In agreement with previous studies showing that 
HDAC inhibitors increased gene expression and reversed 
the reduction of histone H3 acetylation levels in rat neu-
roinflammation and brain damage models [57, 58], we 
found in this study that SAHA suppressed H3K9 acetyla-
tion levels and then reduced TLR4 gene expression in the 
rat seizures model.
Conclusions
In summary, the study shows that SAHA can suppress 
seizure-induced microglia activation and neuron apop-
tosis, and inhibit TLR4 expression through histone 
acetylation regulation by inhibiting TLR4/MYD88 sign-
aling. This strongly suggests a potential neuroprotec-
tive effect of SAHA against neuroinflammation-induced 
brain damage. These findings provide new insights into 
the treatment of epilepsy and other neurodegenerative 
disorders.
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Fig. 6 SAHA inhibited TLR4 gene transcription by histone acetylation regulation. Histones interaction with the 5′ region of the TLR4 gene were 
examined with ChIP assays using anti‑acetyl histone a H3 and b H3K9 antibodies. Rabbit IgG was used as a negative control. The “input” lanes repre‑
sent the results of PCR using non‑immunoprecipitated chromatin as templates. The 5′ regions of the TLR4 gene, with the 5′ regions of the GAPDH 
gene as an internal reference, were amplified by PCR from the immunoprecipitated chromatin. The DNA bands for c H3 and d H3K9 were quantified 
by densitometry and data expressed as mean ± SD (n = 3). Bars expressed as the ratio of optical density (OD) of the samples to the corresponding 
internal standard (GAPDH). *P < 0.05; **P < 0.01; ***P < 0.001; #P > 0.05
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